{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:24Z","timestamp":1794049644404,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1160.18.300"],"award-info":[{"award-number":["NWA.1160.18.300"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bdrocan BV"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioids continue to be widely prescribed for chronic noncancer pain, despite the awareness that opioids provide only short-time pain relief, lead to dose accumulation, have numerous adverse effects, and are difficult to wean. As an alternative, we previously showed advantages of using pharmaceutical-grade cannabis in a population of chronic pain patients with fibromyalgia. It remains unknown whether combining an opioid with pharmaceutical-grade cannabis has advantages, such as fewer side effects from lesser opioid consumption in chronic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Trial design<\/jats:italic>\n                      : a single-center, randomized, three-arm, open-label, exploratory trial.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial population<\/jats:italic>\n                      : 60 patients with fibromyalgia according to the 2010 definition of the American College of Rheumatologists.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Intervention<\/jats:italic>\n                      : Patients will be randomized to receive up to 4 daily 5\u00a0mg oral oxycodone sustained release (SR) tablet, up to 5 times 150\u00a0mg inhaled cannabis (Bediol\u00ae, containing 6.3% \u0394\n                      <jats:sup>9<\/jats:sup>\n                      -tetrahydrocannabinol and 8% cannabidiol), or the combination of both treatments. Treatment is aimed at self-titration with the daily maximum doses given. Treatment will continue for 6\u00a0weeks, after which there is a 6-week follow-up period.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Main trial endpoint<\/jats:italic>\n                      : The number of side effects observed during the course of treatment using a composite adverse effect score that includes the following 10 symptoms: dizziness (when getting up), sleepiness, insomnia, headache, nausea, vomiting, constipation, drug high, hallucinations, and paranoia.\n                    <\/jats:p>\n                    <jats:p>Secondary and tertiary endpoints include pain relief and number of oxycodone doses and cannabis inhalations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The trial is designed to determine whether self-titration of oxycodone and cannabis will reduce side effects in chronic pain patients with fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration {2a and 2b}<\/jats:title>\n                    <jats:p>\n                      EU trial register 2019\u2013001861-33, URL\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\">https:\/\/www.clinicaltrialsregister.eu<\/jats:ext-link>\n                      , on July 17, 2019; World Health Organization International Clinical Trials Research Platform NL7902, URL\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/trialsearch.who.int\">https:\/\/trialsearch.who.int<\/jats:ext-link>\n                      , on July 26, 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07078-6","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T06:02:58Z","timestamp":1674799378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis\/oxycodone combination\u2014the SPIRAL study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-1528","authenticated-orcid":false,"given":"Cornelis Jan","family":"van Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"van Velzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-5209","authenticated-orcid":false,"given":"Arnt","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Olofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Niesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-3945","authenticated-orcid":false,"given":"Albert","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"7078_CR1","doi-asserted-by":"crossref","unstructured":"Bedene A, Dahan A, Rosendaal F, van Dorp E. Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids. Exp Rev Clinl Pharmacol.\u00a02022;5:1081\u201394. (online ahead of print).","DOI":"10.1080\/17512433.2022.2114898"},{"key":"7078_CR2","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2468-2667(19)30128-8","volume":"4","author":"GA Kalkman","year":"2019","unstructured":"Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health. 2019;4:e498\u2013505.","journal-title":"Lancet Public Health"},{"key":"7078_CR3","doi-asserted-by":"publisher","first-page":"e1910223","DOI":"10.1001\/jamanetworkopen.2019.10223","volume":"2","author":"A Bedene","year":"2019","unstructured":"Bedene A, Lijfering WM, Niesters M, van Velzen M, Rosendaal FR, Bouvy ML, Dahan A, van Dorp ELA. Opioid prescription patterns and risk factors associated with opioid use in the Netherlands. JAMA Netw Open. 2019;2:e1910223.","journal-title":"JAMA Netw Open"},{"key":"7078_CR4","unstructured":"TAPTOE consortium. https:\/\/www.taptoeconsortium.nl."},{"key":"7078_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160:860\u20139.","journal-title":"Pain"},{"key":"7078_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3959(03)00163-5","volume":"105","author":"M Naef","year":"2003","unstructured":"Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105:79\u201388.","journal-title":"Pain"},{"key":"7078_CR7","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/s41386-018-0011-2","volume":"43","author":"ZV Cooper","year":"2018","unstructured":"Cooper ZV, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacol. 2018;43:2046\u201355.","journal-title":"Neuropsychopharmacol"},{"key":"7078_CR8","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1111\/bph.14769","volume":"176","author":"X Chen","year":"2019","unstructured":"Chen X, Cowan A, Inan S, Geller EB, Meissler JJ, Rawls SM, Tallarida RJ, Tallarida CS, Watson MN, Adler MW, Eisenstein TK. Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB1 and CB2 receptors. Br J Pharmacol. 2019;176:3378\u201389.","journal-title":"Br J Pharmacol"},{"key":"7078_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1177\/1060028019854221","volume":"53","author":"M O\u2019Connell","year":"2019","unstructured":"O\u2019Connell M, Sandgren M, Frantzen L, Bower E, Erickson B. Medical cannabis: effects on opioid and benzodiazepine requirements for pain control. Ann Pharmacother. 2019;53:1081\u20136.","journal-title":"Ann Pharmacother"},{"key":"7078_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13643-020-01425-3","volume":"9","author":"BO Okusanya","year":"2020","unstructured":"Okusanya BO, Asaolu IO, Ehiri JE, Kimura LJ, Okechukwu A, Rosales C. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Syst Rev. 2020;9:167.","journal-title":"Syst Rev"},{"key":"7078_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg GL, Katx RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7078_CR12","volume-title":"Encyclopedia of the Neurological Sciences","author":"M Niesters","year":"2013","unstructured":"Niesters M, Dahan A. ibromyalgia. In: Encyclopedia of the Neurological Sciences. 2nd ed. 2013.","edition":"2"},{"key":"7078_CR13","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1038\/s41598-018-23107-w","volume":"8","author":"M Brines","year":"2018","unstructured":"Brines M, Culver C, Ferdousi M, Tannemaat M, van Velzen M, Dahan A, Malik R. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Sci Rep. 2018;8:4734.","journal-title":"Sci Rep"},{"key":"7078_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000503625","volume":"26","author":"S Oudejans","year":"2020","unstructured":"Oudejans S, de Weert-van OG, Spits M, de Wildt W, Merkx M, Dekker J, Visch I, Goudrian A. A self-reported version of the measurements in the addictions for triage and evaluation-Q: concurrent validity with the MATE 2.1. Eur Addict Res. 2020;26:20\u20137.","journal-title":"Eur Addict Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07078-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T13:36:15Z","timestamp":1701783375000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07078-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7078"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07078-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the protocol has been obtained from the Medical Research and Ethics Committee (MREC) Leiden-Den-Haag-Delft (Leiden University Medical Center, Albinusdreef 2, 2333 RC Leiden, the Netherlands); identifier P19.050, on July 17, 2019. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"All authors give consent for publication provided that they agree with the contents of the paper and their contributions are acknowledged. The sponsors have no influence on the publications process. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"AD received consulting fees and is member of the scientific advisory board of Enalare Therapeutics (USA) and member of the scientific board of MyCB1 Group BV (the Netherlands). AD received grants from ZonMW, the Hague (the Netherlands), and an award from the US Food and Drug Administration (USA). All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"64"}}